INHE 3002 Week 7 Kava Safety Brief Example

What Regulators and Monitors Have Published About Kava, Where the Record Is Thin, and Why Telling a Clinician Is a Conversation Rather Than a Duty

Student Name

Walden University

INHE 3002: Survey of Complementary Health Approaches

Instructor Name

Month Day, Year

What Regulators and Monitors Have Published About Kava, Where the Record Is Thin, and Why Telling a Clinician Is a Conversation Rather Than a Duty

The Approach

Kava is a drink and supplement made from the root of a Pacific Island plant, used traditionally as a ceremonial beverage and sold in the United States as capsules, extracts and teas marketed for relaxation. It belongs to the nutritional category of complementary approaches, since it is taken in by mouth. This brief documents what monitoring and regulatory bodies have published about its safety, states where that record is thin and treats disclosure to clinicians as a communication question.

What Has Been Published

The main safety concern is liver injury. In 2002, the U.S. Food and Drug Administration issued a consumer advisory warning that kava-containing supplements had been linked to reports of severe liver injury, including cases requiring liver transplantation, and several European countries restricted sales around the same time. The federal research center's current summary states that kava has been reported to cause liver damage, including hepatitis and liver failure, and advises people to talk with a health care provider before using it (National Center for Complementary and Integrative Health [NCCIH], 2020). A review of liver toxicity from herbal and dietary supplements lists kava among the products associated with liver injury and discusses factors such as the plant parts used and the extraction method (Stickel & Shouval, 2015).

Where the Record Is Thin

The record has three weaknesses. First, it rests largely on case reports, which show that injury occurred in people taking kava but cannot show how often it happens or whether kava alone was the cause in each case. Second, adverse event reporting for supplements is voluntary for consumers and clinicians. The FDA's adverse event reporting system for foods and supplements collects what is submitted, and the agency notes that a report does not establish that a product caused the event (U.S. Food and Drug Administration [FDA], 2024). Underreporting is likely, so the true number of cases is unknown in both directions. Third, products differ: extracts made with solvents from different plant parts may carry different risks than traditional water-based drinks, but labels rarely make that distinction clear.

What Can and Cannot Be Said

On this record, the brief can say that liver injury has been reported repeatedly with kava, that regulators in several countries have acted on those reports and that the federal center advises caution. It cannot say how likely injury is for any one user, or that traditional preparations carry the same risk as concentrated extracts. Both statements would go beyond the record.

Disclosure as a Communication Topic

Because kava can harm the liver and may interact with other substances that affect the liver, it matters that a person's clinicians know they are taking it. National survey data show that a large share of adults who use complementary approaches do not tell their primary care physicians, often because they were not asked or assumed it was not important (Jou & Johnson, 2016). Framing disclosure as a duty the client has failed to meet tends to make the conversation harder. Framing it as a routine question, asked by the clinician about every supplement and treated without judgment, makes it easier for clients to answer. The safety brief's practical recommendation is therefore aimed at both sides: clinicians should ask about supplements by name, and anyone using kava should mention it at every visit, especially when starting a new medication.

References

Jou, J., & Johnson, P. J. (2016). Nondisclosure of complementary and alternative medicine use to primary care physicians: Findings from the 2012 National Health Interview Survey. JAMA Internal Medicine, 176(4), 545-546. https://doi.org/10.1001/jamainternmed.2015.8593

National Center for Complementary and Integrative Health. (2020). Kava. https://www.nccih.nih.gov/health/kava

Stickel, F., & Shouval, D. (2015). Hepatotoxicity of herbal and dietary supplements: An update. Archives of Toxicology, 89(6), 851-865. https://doi.org/10.1007/s00204-015-1471-3

U.S. Food and Drug Administration. (2024). CFSAN adverse event reporting system (CAERS). https://www.fda.gov/food/compliance-enforcement-food/cfsan-adverse-event-reporting-system-caers